Sarepta Therapeutics Gets FDA Fast Track Designation for Ebola Drug

by Benzinga Staff
September 18, 2012 8:33 AM | 25 seconds read

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

Sarepta Therapeutics,Inc. (NASDAQ: SRPT), a developer of innovative RNA-basedtherapeutics, today announced that the U.S. Food and DrugAdministration (FDA) has granted Fast Track status for thedevelopment of its lead infectious disease drug candidates, AVI-7288and AVI-7537, for the treatment of Marburg virus and Ebola virus,respectively. Sarepta has been developing these platform-basedtherapeutics under a U.S. Department of Defense (DoD) contractmanaged by the Joint Project Manager Transformational MedicalTechnologies (JPM-TMT) Project Management Office, a component of theJoint Program Executive Office for Chemical and Biological Defense(JPEO-CBD).

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsFDA

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.